Phase 2 N=29 Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
Corona Virus Infection · SARS-CoV 2 · SARS Pneumonia
Primary: Number of Participants Transferred to Intensive Care Unit (ICU) — 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=557 Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
Actinic Keratoses
Primary: Percentage of Participants With Complete Response at Week 12 — 25.3; 23.0 percentage of participants
N/A N=10 Pilot Study to Evaluate Safety, Tolerability, and Performance of the FAST PV Technology™ in Chronic Dialysis Patients
End Stage Renal Disease
Primary: Evaluate Plasma Volume (PV) and Interstitial Volume (ISV) Using the FAST PV Technology and Iohexol in Patients on Chronic Dialysis Pre-dialysis — 3869; 9152; 3895; 19057…
N/A N=68 Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Myopic Population; Part 2
Visual Acuity
Primary: Visual Performance LogMAR — -0.12; -0.13; -0.06; -0.04 logMAR
Phase 2 N=6 A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)
Limb-Girdle Muscular Dystrophy, Type 2D
Primary: Number of Participants With Adverse Events (AEs). — 1; 3; 2; 0 Participants
Phase 2 N=941 CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
COVID-19 · Coronavirus · Coronavirus Infection
Primary: Score on the WHO 11-point Ordinal Scale for Clinical Improvement at 14 Days — 2; 2 score on a scale
N/A N=23 Functional Dyspepsia Hypnosis
Functional Dyspepsia
Primary: Percent of Participants That Complete the Hypnotherapy Program — 22 Participants
Phase 2 N=25 Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects
SARS-CoV-2 (Covid19)
Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) — 3; 4; 5; 2 Participants
N/A N=21 Fully Automated Closed Loop Control in Adolescents With Type 1 Diabetes
Type 1 Diabetes
Primary: Percentage of Time From Dinner Time Until Midnight With Blood Glucose in Range 70-180 mg/dL in the Unannounced Meal — 83; 53 %Time in Range (TIR) — p=0.004
Phase 2 N=27 Smell Changes & Efficacy of Nasal Theophylline
Olfactory Disorder · Anosmia · Viral Infection
Primary: Number of Patients With Improvement in Global Rating of Smell Change — 4; 3 Participants
Phase 2 N=88 A Study in Adults and Adolescents With Angelman Syndrome (STARS)
Angelman Syndrome
Primary: Incidence of Adverse Events in Placebo and Active Treatment Groups — 25; 27; 25; 23 Participants
Phase 3 N=60 A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial
Benign Prostatic Hyperplasia
Primary: Operative Time — 101; 126 minutes
Phase 2 N=8 A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy
LMNA-Related Dilated Cardiomyopathy
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 8 Participants
Phase 2 N=40 COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial
Infection Viral · Thromboses, Venous · COVID-19
Primary: Safety of In-hospital Thromboprophylaxis as Assessed by Number of Participants With ISTH-defined Clinically-relevant Bleeding Events During Hospitalization — 0…
N/A N=6 Covered vs Uncovered Metal Stents for Palliative Biliary Decompression in Inoperable Malignant Distal Bile Duct Obstruction
Distal Bile Duct Obstruction
Primary: Rate of Long-term Stent Failure — 0; 2 Participants